Achieve Life Sciences (ACHV) Competitors $2.66 +0.11 (+4.31%) Closing price 04:00 PM EasternExtended Trading$2.70 +0.03 (+1.32%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACHV vs. XOMA, CBIO, VNDA, CDXS, IRWD, AGEN, SGMO, DOMH, FBIO, and SABSShould you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include XOMA Royalty (XOMA), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), Agenus (AGEN), Sangamo Therapeutics (SGMO), Dominari (DOMH), Fortress Biotech (FBIO), and SAB Biotherapeutics (SABS). These companies are all part of the "biotechnology" industry. Achieve Life Sciences vs. Its Competitors XOMA Royalty Crescent Biopharma Vanda Pharmaceuticals Codexis Ironwood Pharmaceuticals Agenus Sangamo Therapeutics Dominari Fortress Biotech SAB Biotherapeutics Achieve Life Sciences (NASDAQ:ACHV) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Which has better valuation & earnings, ACHV or XOMA? XOMA Royalty has higher revenue and earnings than Achieve Life Sciences. XOMA Royalty is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchieve Life SciencesN/AN/A-$39.83M-$1.46-1.82XOMA Royalty$28.49M13.47-$13.82M-$1.55-20.48 Which has more volatility and risk, ACHV or XOMA? Achieve Life Sciences has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, XOMA Royalty has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. Does the media prefer ACHV or XOMA? In the previous week, XOMA Royalty had 15 more articles in the media than Achieve Life Sciences. MarketBeat recorded 15 mentions for XOMA Royalty and 0 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 1.88 beat XOMA Royalty's score of 0.82 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Achieve Life Sciences Very Positive XOMA Royalty Positive Is ACHV or XOMA more profitable? Achieve Life Sciences has a net margin of 0.00% compared to XOMA Royalty's net margin of -27.57%. XOMA Royalty's return on equity of 2.63% beat Achieve Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Achieve Life SciencesN/A -193.49% -116.68% XOMA Royalty -27.57%2.63%0.97% Do analysts prefer ACHV or XOMA? Achieve Life Sciences currently has a consensus price target of $16.00, suggesting a potential upside of 501.50%. XOMA Royalty has a consensus price target of $69.50, suggesting a potential upside of 118.97%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than XOMA Royalty.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67XOMA Royalty 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals have more ownership in ACHV or XOMA? 33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are held by institutional investors. 3.0% of Achieve Life Sciences shares are held by insiders. Comparatively, 7.2% of XOMA Royalty shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAchieve Life Sciences and XOMA Royalty tied by winning 8 of the 16 factors compared between the two stocks. Get Achieve Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHV vs. The Competition Export to ExcelMetricAchieve Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$135.93M$2.48B$5.70B$9.79BDividend YieldN/A1.68%3.77%4.10%P/E Ratio-1.8221.5730.8625.29Price / SalesN/A547.70403.8888.61Price / CashN/A25.4525.2228.45Price / Book4.365.559.516.00Net Income-$39.83M$31.83M$3.26B$265.34M7 Day Performance8.57%4.89%4.49%2.78%1 Month Performance-0.75%4.00%5.21%1.51%1 Year Performance-40.89%11.05%31.91%25.41% Achieve Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHVAchieve Life Sciences2.3531 of 5 stars$2.66+4.3%$16.00+501.5%-43.3%$135.93MN/A-1.8220Positive NewsXOMAXOMA Royalty4.4097 of 5 stars$27.23+2.8%$69.50+155.2%+11.5%$317.12M$28.49M-23.6810Earnings ReportAnalyst RevisionGap DownCBIOCrescent Biopharma3.817 of 5 stars$12.90+0.4%$25.50+97.7%N/A$251.21M$10K-0.3750VNDAVanda Pharmaceuticals4.466 of 5 stars$4.19-0.2%$16.50+293.8%-16.2%$248.17M$198.77M-3.71290News CoverageGap UpCDXSCodexis3.6452 of 5 stars$2.80+1.1%$11.00+292.9%+3.4%$229.48M$59.35M-2.83250News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionIRWDIronwood Pharmaceuticals4.3993 of 5 stars$0.84-6.8%$4.94+490.7%-76.2%$145.14M$351.41M-16.72220AGENAgenus3.9935 of 5 stars$4.27-11.0%$16.33+282.5%-12.3%$131.60M$103.46M-0.49440Earnings ReportAnalyst DowngradeAnalyst RevisionSGMOSangamo Therapeutics3.0465 of 5 stars$0.44-3.6%$4.50+921.8%-34.1%$106.53M$57.80M-1.52480News CoveragePositive NewsAnalyst UpgradeShort Interest ↓Analyst RevisionGap UpDOMHDominari0.6596 of 5 stars$5.33-7.0%N/A+305.1%$83.91M$18.15M-1.184News CoverageEarnings ReportAnalyst UpgradeFBIOFortress Biotech2.3766 of 5 stars$1.92+5.5%$21.00+993.8%+14.0%$53.82M$57.67M-0.86170Earnings ReportGap UpSABSSAB Biotherapeutics2.6877 of 5 stars$2.02-8.2%$11.00+444.6%-8.5%$22.90M$1.32M-0.51140 Related Companies and Tools Related Companies XOMA Alternatives CBIO Alternatives VNDA Alternatives CDXS Alternatives IRWD Alternatives AGEN Alternatives SGMO Alternatives DOMH Alternatives FBIO Alternatives SABS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACHV) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access